PRME
Price
$1.46
Change
-$0.00 (-0.00%)
Updated
Jun 13 closing price
Capitalization
191.69M
52 days until earnings call
SONN
Price
$1.15
Change
-$0.03 (-2.54%)
Updated
Jun 13 closing price
Capitalization
3.64M
Interact to see
Advertisement

PRME vs SONN

Header iconPRME vs SONN Comparison
Open Charts PRME vs SONNBanner chart's image
Prime Medicine
Price$1.46
Change-$0.00 (-0.00%)
Volume$1.17M
Capitalization191.69M
Sonnet BioTherapeutics Holdings
Price$1.15
Change-$0.03 (-2.54%)
Volume$22.4K
Capitalization3.64M
PRME vs SONN Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. SONN commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Buy and SONN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (PRME: $1.46 vs. SONN: $1.15)
Brand notoriety: PRME and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 59% vs. SONN: 65%
Market capitalization -- PRME: $191.69M vs. SONN: $3.64M
PRME [@Biotechnology] is valued at $191.69M. SONN’s [@Biotechnology] market capitalization is $3.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 0 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 0 green, 5 red.
According to our system of comparison, PRME is a better buy in the long-term than SONN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 5 TA indicator(s) are bullish while SONN’s TA Score has 4 bullish TA indicator(s).

  • PRME’s TA Score: 5 bullish, 4 bearish.
  • SONN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than SONN.

Price Growth

PRME (@Biotechnology) experienced а -13.61% price change this week, while SONN (@Biotechnology) price change was -8.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.75%. For the same industry, the average monthly price growth was +12.94%, and the average quarterly price growth was +4.02%.

Reported Earning Dates

PRME is expected to report earnings on Aug 06, 2025.

SONN is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-0.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($192M) has a higher market cap than SONN($3.64M). SONN YTD gains are higher at: -21.233 vs. PRME (-50.000). SONN has higher annual earnings (EBITDA): -13.33M vs. PRME (-200M). PRME has more cash in the bank: 144M vs. SONN (4.86M). SONN has less debt than PRME: SONN (111K) vs PRME (121M). PRME has higher revenues than SONN: PRME (3.85M) vs SONN (1M).
PRMESONNPRME / SONN
Capitalization192M3.64M5,273%
EBITDA-200M-13.33M1,500%
Gain YTD-50.000-21.233235%
P/E RatioN/A0.29-
Revenue3.85M1M385%
Total Cash144M4.86M2,962%
Total Debt121M111K109,009%
FUNDAMENTALS RATINGS
PRME vs SONN: Fundamental Ratings
PRME
SONN
OUTLOOK RATING
1..100
6166
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
6491
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (38) in the null industry is in the same range as SONN (52). This means that PRME’s stock grew similarly to SONN’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as SONN (100). This means that PRME’s stock grew similarly to SONN’s over the last 12 months.

PRME's SMR Rating (95) in the null industry is in the same range as SONN (98). This means that PRME’s stock grew similarly to SONN’s over the last 12 months.

PRME's Price Growth Rating (64) in the null industry is in the same range as SONN (91). This means that PRME’s stock grew similarly to SONN’s over the last 12 months.

SONN's P/E Growth Rating (96) in the null industry is in the same range as PRME (100). This means that SONN’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMESONN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
82%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 20 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Aroon
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLESX14.170.05
+0.35%
GS Energy Infrastructure Fd R6 Shares
MNDFX8.24-0.05
-0.60%
Manning & Napier Disciplined Value I
GICAX15.05-0.16
-1.05%
Goldman Sachs Intl Sm Cp Insghts A
SROIX12.81-0.15
-1.16%
Calamos Antetokounmpo Sustainable Eqs I
QLSCX25.57-0.44
-1.69%
Federated Hermes MDT Small Cap Core R6

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
N/A
CRSP - PRME
63%
Loosely correlated
+0.19%
BEAM - PRME
57%
Loosely correlated
-2.18%
RXRX - PRME
57%
Loosely correlated
-4.84%
CRBU - PRME
51%
Loosely correlated
-4.31%
IPSC - PRME
50%
Loosely correlated
-4.10%
More

SONN and

Correlation & Price change

A.I.dvisor tells us that SONN and ABSI have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and ABSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-2.54%
ABSI - SONN
27%
Poorly correlated
-2.11%
DWTX - SONN
27%
Poorly correlated
-10.23%
PRME - SONN
26%
Poorly correlated
N/A
IGMS - SONN
26%
Poorly correlated
N/A
PHAR - SONN
25%
Poorly correlated
-7.05%
More